Real‐world effectiveness and safety of the LAight‐therapy in patients with hidradenitis suppurativa

Abstract

SummaryBackground and objectivesHidradenitis suppurativa (HS)/Acne inversa (Ai) is a chronic debilitating disease with limited therapy options. The device‐based LAight therapy was approved in Europe in 2017. The aim of this study was to evaluate the effect of real‐world care with at least one treatment with LAight therapy on disease activity and burden in 3,437 patients.Patients and MethodsPatients were included in the analysis if they had a diagnosis of HS and received at least one treatment. The endpoints Hidradenitis Suppurativa Severity Score System (IHS4), pain on the numeric rating scale (pain‐NRS) and Dermatology Life Quality Index (DLQI) were analyzed using a linear mixed model for repeated measures (MMRM) over 26 weeks of care with LAight therapy. Furthermore, responder rates were calculated for all endpoints, and the therapy's safety profile and patient satisfaction were thoroughly examined.ResultsA significant decrease in IHS4, pain‐NRS, and DLQI was achieved during 26 weeks of care with LAight. The BMI at baseline had a significant negative effect on therapy response for pain‐NRS and DLQI.ConclusionsThis study confirms that LAight therapy leads to satisfactory disease control in all stages of severity and is a valuable addition to the therapeutic repertoire of HS.